Urticaria Facticia Treatment With Omalizumab (UFO)

NCT ID: NCT02169115

Last Updated: 2020-11-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 61 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-12-31
• Study Completion Date: 2014-12-31

Brief Summary

Urticaria is a very frequent skin condition characterized by transient wheal and flare type skin reactions associated with severe pruritus. In Europe alone, more than 5 million patients are thought to suffer from persisting urticaria symptoms, which either occur spontaneously, i.e. in chronic spontaneous urticaria (CSU), or as a result of environmental physical stimuli such as friction, pressure, UV irradiation or cold (physical urticaria). Urticaria factitia (also known as dermographic urticaria and symptomatic dermographism) is characterized by whealing and itching following a minor stroking pressure, rubbing or scratching of the skin. The majority of patients with urticaria factitia benefits from treatment with nonsedating antihistamines. Some patients, however, do not achieve adequate symptom control even with updosing of antihistamines and may suffer from substantial quality of life impairment . Since even very minor stroking of the skin can lead to the development of wheals and severe itching, these patients are for example limited in their choice of clothing and are impaired in their social interaction and partnership.

In all patients with a history of wheals after stroking of the skin, a provocation test should be performed. This can be done by stroking of the skin lightly with a smooth blunt object (e.g. the tip of a closed ball point pen or a wooden spatula) or a purpose-built instrument, known as a dermographometer. For the diagnosis of symptomatic dermographism, the smooth blunt object should be held perpendicular to the skin and should be used to apply a light stroking pressure to the skin of the upper back or volar forearm. The reaction is considered positive in patients who show a weal response and report pruritus at the site of provocation.

Patients with a positive test reaction should be evaluated for individual pressure thresholds. For this purpose a provocation device (FricTest) has been developed that allows for reproducible and standardized threshold testing. Threshold testing enables physicians to assess disease severity and treatment response more precisely.

Conditions

Symptomatic Dermographism

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Omalizumab 150mg

Group Type: EXPERIMENTAL

Omalizumab

Intervention Type: DRUG

150mg, s.c., every 4 weeks

Omalizumab 300mg

Group Type: EXPERIMENTAL

Omalizumab

Intervention Type: DRUG

300mg, s.c., every 4 weeks

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo, s.c., every 4 weeks

Interventions

Omalizumab

150mg, s.c., every 4 weeks

Intervention Type: DRUG

Omalizumab

300mg, s.c., every 4 weeks

Intervention Type: DRUG

Placebo

Placebo, s.c., every 4 weeks

Intervention Type: DRUG

Other Intervention Names

Xolair; Xolair

Eligibility Criteria

Inclusion Criteria

• Adults (18-75 years)
• Informed consent signed and dated
• Able to read, understand and willing to sign the informed consent form and abide with study procedures
• Diagnosis of UF lasting for at least 6 months
• Willing, committed and able to return for all clinic visits and complete all study-related procedures, including willingness to have SC injections administered by a qualified person
• In females of childbearing potential: Negative pregnancy test; females willing to use highly effective contraception (Pearl-Index < 1). A woman will be considered not of childbearing potential if she is post-menopausal for greater than two years or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy)
• No participation in other clinical trials 4 weeks before and after participation in this study

Exclusion Criteria

• Patients with acute urticaria
• Concurrent/ongoing treatment with immunosuppressives (e.g. systemic steroids, cyclosporine, methotrexate, dapsone or others) within 4 weeks or 5 half lives prior to day 0, whichever is longer
• Significant medical condition rendering the patient immunocompromised or not suitable for a clinical trial
• Significant concomitant illness that would adversely affect the subject's participation or evaluation in this study
• History of malignancies within five years prior to screening other than a successfully treated non-metastatic cutaneous, basal, or squamous cell carcinoma and/or in situ cancer
• Presence of clinically significant laboratory abnormalities
• Lactating females or pregnant females
• Subjects for whom there is concern about compliance with the protocol procedures
• Any medical condition which, in the opinion of the Investigator, would interfere with participation in the study or place the subject at risk
• History of substance abuse (drug or alcohol) or any other factor (e.g., serious psychiatric condition) within the last 5 years that could limit the subject's ability to comply with study procedures
• Subjects who are detained officially or legally to an official institute
• Previous use of omalizumab within the last 6 months
• Intake of antihistamines or leukotriene antagonists within 4 days prior to visit 1
• Intake of oral corticosteroids within 14 days prior to visit 1
• Use of depot corticosteroids or chronic systemic corticosteroids within 21 days before beginning of the study
• Known hypersensitivity to any ingredients, including excipients (sucrose, histidine, polysorbate 20) of the study medication or drugs related to omalizumab (e.g.: monoclonal antibodies, polyclonal gammaglobulin)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

Charite University, Berlin, Germany

OTHER

Sponsor Role: lead

Responsible Party

Martin Metz

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Martin Metz, MD

Role: PRINCIPAL_INVESTIGATOR

Charité University

Locations

University Dermatology Freiburg

Freiburg im Breisgau, , Germany

Dermatology University Mainz

Mainz, , Germany

Countries

Germany

References

Maurer M, Schutz A, Weller K, Schoepke N, Peveling-Oberhag A, Staubach P, Muller S, Jakob T, Metz M. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017 Sep;140(3):870-873.e5. doi: 10.1016/j.jaci.2017.01.042. Epub 2017 Apr 4. No abstract available.

Reference Type: DERIVED

PMID: 28389391 (View on PubMed)

Other Identifiers

2011-005615-87

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CIGE025EDE17T

Identifier Type: -

Identifier Source: org_study_id